From the 1980s, therapeutic protein drugs — monoclonal antibodies, proteins, antibody-drug conjugates, bispecific antibodies, etc. — have been widely employed in the treatment of HIV, tumors and other ...
Since the mid-1980s, therapeutic monoclonal antibodies have become the fastest-growing class of therapeutics. This was due to the numerous pharmaceutical companies that were trying to find more drug ...
First in human (FIH) clinical trials of bispecific immunostimulatory antibodies commonly require a low starting dose based on a minimum anticipated biological effect level (MABEL) approach. To ...
Drug safety and efficacy are key concerns for manufacturers during the long, complex, and costly drug development process. Regulatory agencies now expect that immune responses caused by drug treatment ...
As the use of immunoassays to discover, detect, and quantitate proteins from a variety of biological samples has greatly expanded, so have requirements for enhanced sensitivity, precision, reliability ...
As scientists continue to expand the utility of biomarkers in basic and applied life science research, advances in immunoassay technologies further empower these efforts by improving the way key ...
Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to ...
Having a robust immunogenicity assay for accurate evaluation of ADA in animal models is important for enabling effective decision-making during development. Learn how a robust anti-drug antibody assay ...
HERCULES, Calif., April 21, 2020 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, has extended its range of recombinant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback